<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02745951</url>
  </required_header>
  <id_info>
    <org_study_id>15 - 311</org_study_id>
    <nct_id>NCT02745951</nct_id>
  </id_info>
  <brief_title>HELIox CardiOPlegia Trial During Cardiac surgERy</brief_title>
  <acronym>HELICOPTER-1</acronym>
  <official_title>HELIox CardiOPlegia Trial During Cardiac surgERy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HELICOPTER-1 Trial is a single centre pilot study to determine the feasibility of
      administering Heliox in cardioplegia during cardiac surgery and whether it has the potential
      to reduce the incidence and severity of myocardial ischemia during and after cardiac surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HELICOPTER-1 Trial is a single centre, randomized trial evaluating the feasibility of
      administration of Heliox for prevention of myocardial ischemia in patients undergoing cardiac
      surgery. Half of the study population will be randomly assigned to the receive cardioplegia
      enriched with a 70:30 (Helium:Oxygen) Heliox mixture, while the other half will be randomized
      to receive the current clinical standard of care (nitrogen and oxygen in cardioplegia).

      Subjects will be followed up daily during their post-operative course in hospital for
      clinical outcomes. A 30-day phone follow-up will be conducted for vital status and MI.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of using Heliox to oxygenate the blood cardioplegia</measure>
    <time_frame>30 days from the intervention</time_frame>
    <description>To determine the feasibility of using Heliox to oxygenate the blood cardioplegia. Feasibility will be measured according to subject enrollment rates and to measurement of the blood gas content of the cardioplegia solutions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New Myocardial Infarction</measure>
    <time_frame>30 days from the intervention</time_frame>
    <description>Myocardial infarction (MI) will be defined according to the Third Universal Definition of MI using the following two criteria:
Serum levels of Troponin I: Values more than 10 times the 99th percentile of the upper limit from a normal baseline. If preoperative enzyme levels are abnormal, the post-operative enzymes must be greater than the baseline plus 10 times the upper limit from a normal baseline.
ECG: At least one of the following i) New left bundle branch block ii) Development of new pathological Q waves iii) Imaging evidence of new loss of viable myocardium or new regional wall abnormality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>C.Surgical Procedure; Cardiac</condition>
  <arm_group>
    <arm_group_label>Heliox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cardioplegia enriched with a 70:30 (Helium:Oxygen) Heliox mixture while the patient is on cardiopulmonary bypass</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cardioplegia enriched with a Nitrogen and Oxygen mixture while the patient is on cardiopulmonary bypass</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Heliox</intervention_name>
    <description>Half of the study population will be randomly assigned to receive cardioplegia enriched with a 70:30 (Helium:Oxygen) via a D100 pediatric oxygenator. The Heliox itself will need to be administered via an oxygen regulator using a low flowmeter.</description>
    <arm_group_label>Heliox</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>The other half will be randomized to Nitrogen:Oxygen mixture. This will be done through the standard of care cardioplegia apparatus. There will be no novel interventions administered in this group.</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Cardiac surgery with CPB where use of a coronary sinus catheter is indicated

        Exclusion Criteria:

          -  Patient refusal

          -  Recent myocardial infarction (less than 7 days old)

          -  Left ventricular ejection fraction less than 30%

          -  Known pregnancy on date of surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Mazer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Mazer, MD</last_name>
    <phone>416-864-5825</phone>
    <email>mazerd@smh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Constantine Dalamagas, RRT, CPC</last_name>
    <phone>416-864-6060</phone>
    <phone_ext>5753</phone_ext>
    <email>DalamagasC@smh.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Constantine Dalamagas, RRT, CPC</last_name>
      <phone>416-864-6060</phone>
      <phone_ext>5753</phone_ext>
      <email>DalamagasC@smh.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiopulmonary bypass</keyword>
  <keyword>cardioplegia</keyword>
  <keyword>cardioprotection</keyword>
  <keyword>coronary artery bypass graft surgery</keyword>
  <keyword>heliox</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

